{
    "success": true,
    "data": {
        "id": 1713937,
        "msgid": "through-rights-issue-pyridam-farma-pyfa-explores-expansion-and-acquisition-potential-1777711913",
        "date": "2026-05-02 15:00:00",
        "title": "Through Rights Issue, Pyridam Farma (PYFA) Explores Expansion and Acquisition Potential",
        "author": "Sakina Rakhma Diah Setiawan",
        "source": "KOMPAS",
        "tags": "",
        "topic": "Business",
        "summary": "PT Pyridam Farma Tbk (PYFA) has secured shareholder approval for its second Rights Issue (PMHMETD II) in April 2026, aiming to issue up to 5.7 billion new shares and warrants to fund expansion and strengthen its integrated healthcare ecosystem. This strategic move is intended to enhance competitiveness, integrate advanced technology in pharmaceutical services, and create long-term value for shareholders. The process is scheduled to conclude by the third quarter of 2026, following OJK approval in late June.",
        "content": "<p>JAKARTA, KOMPAS.com - PT Pyridam Farma Tbk (PYFA) is implementing a\nCapital Increase with Pre-emptive Rights II (PMHMETD II), or rights\nissue, after obtaining shareholder approval at an Extraordinary General\nMeeting of Shareholders (EGMS) held in April 2026.<\/p>\n<p>This approval marks an important milestone in the company\u2019s\ntransformation journey to build an integrated healthcare services\necosystem, in line with efforts to enhance competitiveness and create\nlong-term value for shareholders.<\/p>\n<p>In its prospectus, the company plans to issue new shares in a maximum\namount of 5.7 billion shares with a nominal value of Rp 100 per share,\naccompanied by the issuance of warrants in accordance with applicable\nprovisions.<\/p>\n<p>This step is part of the strategy to accelerate expansion and\nstrengthen its position within the integrated healthcare industry\necosystem.<\/p>\n<p>\u201cThe company wishes to express its gratitude for the shareholders\u2019\ntrust. Naturally, with the approval we have received, we will focus on\ncompleting our ecosystem. The company views that as a pharmaceutical\ncompany, providing the best products and healthcare services with\ncutting-edge technology to the public is our obligation and\nresponsibility,\u201d she stated in an official release on Saturday\n(2\/5\/2026).<\/p>\n<p>In addition to the issuance of new shares, she added, the company is\nalso including warrants as part of the corporate action structure.<\/p>\n<p>The issuance of these warrants is expected to provide added value to\nshareholders who exercise their rights, while opening up additional\ncapital potential for the company in the future through warrant\nconversions.<\/p>\n<p>Sinta added that the company targets the rights issue process to\nproceed gradually, starting from shareholder approval in April 2026 to\nobtaining the effectiveness statement from the OJK by the end of June\n2026.<\/p>\n<p>\u201cSubsequently, the pre-emptive rights exercise period is scheduled to\ntake place in July 2026, with the entire series of corporate actions\ntargeted to be completed in the third quarter of 2026,\u201d she further\nstated.<\/p>\n<p>\u201cAnd the creation of long-term value for all stakeholders, in line\nwith good corporate governance principles,\u201d she concluded.<\/p>",
        "url": "https:\/\/jawawa.id\/newsitem\/through-rights-issue-pyridam-farma-pyfa-explores-expansion-and-acquisition-potential-1777711913",
        "image": ""
    },
    "sponsor": "Okusi Associates",
    "sponsor_url": "https:\/\/okusiassociates.com"
}